CTLA4 and hypophysitis: It is thus common to find autoantibodies in the mouse models of anti–CTLA-4–induced irAES, in particular anti-pituitary antibodies associated with hypophysitis development, which is a frequent adverse event observed in patients treated with ipilimumab (Iwama et al., 2014).